EyeGene Inc. (185490.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩1,749 (+4.11%) as of
Key statistics
- Market cap
- 75.60B
- Dividend yield
- 0.00%
- 52-week range
- 1,182.00 – 2,805.00
- Beta
- 0.70
- Revenue (TTM)
- 4.48B
- Profit margin
- 0.00%
- Volume
- 54.02k
About EyeGene Inc.
EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. Its product pipeline comprises EG-Mirotin, which has completed Phase 2a clinical trial to treat diabetic retinopathy; EG-Decorin which completed Phase 2 clinical trial for the treatment of pressure ulcers and wound healing; and EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury. It also develops EG-HZ, which has completed phase 1 clinical trial for the treatment of herpes zoster; EG-HPV which completed Phase 1 clinical trial to treat cervical cancer; EG-COVID that is in phase I clinical trial for the treatment of covid; and EG-TB for the tuberculosis vaccine and is in preclinical trial. In addition, the company offers vitalDB for beautiful vitality. EyeGene Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Seoul, South Korea
- Employees
- 47
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.